INDO US BIOTECH Financial Statement Analysis
|
||
|
The Revenues of INDO US BIOTECH have increased by 42.56% YoY .
The Earnings Per Share (EPS) of INDO US BIOTECH has increased by 96.84 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INDO US BIOTECH Last 5 Annual Financial Results
[BOM: 541304|NSE : INDOUS]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹104 Cr | ₹73 Cr | ₹62 Cr | ₹50 Cr | ₹40 Cr |
| Expenses | ₹85 Cr | ₹62 Cr | ₹52 Cr | ₹43 Cr | ₹35 Cr |
| Operating Profit (Excl OI) | ₹19 Cr | ₹11 Cr | ₹9.39 Cr | ₹6.93 Cr | ₹5.51 Cr |
| Other Income | ₹0.18 Cr | ₹0.32 Cr | ₹0.02 Cr | ₹0.18 Cr | ₹0.04 Cr |
| Interest | ₹1.49 Cr | ₹1.52 Cr | ₹1.20 Cr | ₹1.20 Cr | ₹1.18 Cr |
| Depreciation | ₹1.10 Cr | ₹0.80 Cr | ₹0.83 Cr | ₹0.42 Cr | ₹0.25 Cr |
| Profit Before Tax | ₹17 Cr | ₹8.80 Cr | ₹7.39 Cr | ₹5.49 Cr | ₹4.13 Cr |
| Profit After Tax | ₹16 Cr | ₹8.25 Cr | ₹7.24 Cr | ₹5.24 Cr | ₹5.10 Cr |
| Earnings Per Share (Rs) | ₹8.11 | ₹4.12 | ₹7.22 | ₹5.71 | ₹8.40 |
| PAT Margin (%) | 15.67 | 11.33 | 11.73 | 10.46 | 12.72 |
| ROE(%) | 23.03 | 14.08 | 15.51 | 17.34 | 26.87 |
| ROCE(%) | 21.15 | 14.42 | 14.62 | 15.86 | 18.30 |
| Total Debt/Equity(x) | 0.19 | 0.23 | 0.21 | 0.32 | 0.53 |
Key Financials |
||
| Market Cap | : | ₹ 269.5 Cr |
| Revenue (TTM) | : | ₹ 109.9 Cr |
| Net Profit(TTM) | : | ₹ 17.8 Cr |
| EPS (TTM) | : | ₹ 8.9 |
| P/E (TTM) | : | 15.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDO US BIOTECH | 2.6% | 0.8% | -48.2% |
| BOMBAY BURMAH TRADING CORPORATION | -0.8% | 0.6% | -32% |
| KAVERI SEED COMPANY | -2.1% | -3.5% | 3% |
| VENKYS (INDIA) | -12.4% | -10.5% | -29.5% |
| BOMBAY SUPER HYBRID SEEDS | -1.2% | -4.3% | -26.4% |
| MANGALAM GLOBAL ENTERPRISE | -3.7% | -17.1% | 14.6% |
| HARRISONS MALAYALAM | 0.1% | -7.2% | -33.7% |
| TIERRA AGROTECH | -10.9% | 31.8% | -24.2% |
| NATH BIOGENES (INDIA) | -0.5% | -6.1% | -11.6% |
INDO US BIOTECH Revenues
[BOM: 541304|NSE : INDOUS]
| Y-o-Y | 42.56 % |
| 5 Yr CAGR | 26.86 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹104 Cr | 42.56 | |
| Mar2024 | ₹73 Cr | 17.96 | |
| Mar2023 | ₹62 Cr | 23.36 | |
| Mar2022 | ₹50 Cr | 24.86 | |
| Mar2021 | ₹40 Cr | - | |
INDO US BIOTECH Operating Profit
[BOM: 541304|NSE : INDOUS]
| Y-o-Y | 75.26 % |
| 5 Yr CAGR | 36.13 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹19 Cr | 75.26 | |
| Mar2024 | ₹11 Cr | 15.03 | |
| Mar2023 | ₹9.39 Cr | 35.52 | |
| Mar2022 | ₹6.93 Cr | 25.70 | |
| Mar2021 | ₹5.51 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 22.99 % |
| 5 Yr CAGR | 7.30 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 18.24% | 22.99 | |
| Mar2024 | 14.83% | -2.50 | |
| Mar2023 | 15.21% | 9.82 | |
| Mar2022 | 13.85% | 0.65 | |
| Mar2021 | 13.76% | - | |
INDO US BIOTECH Profit After Tax
[BOM: 541304|NSE : INDOUS]
| Y-o-Y | 97.15 % |
| 5 Yr CAGR | 33.65 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹16 Cr | 97.15 | |
| Mar2024 | ₹8.25 Cr | 13.96 | |
| Mar2023 | ₹7.24 Cr | 38.25 | |
| Mar2022 | ₹5.24 Cr | 2.73 | |
| Mar2021 | ₹5.10 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 38.31 % |
| 5 Yr CAGR | 5.35 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 15.67 % | 38.31 | |
| Mar2024 | 11.33 % | -3.41 | |
| Mar2023 | 11.73 % | 12.14 | |
| Mar2022 | 10.46 % | -17.77 | |
| Mar2021 | 12.72 % | - | |
INDO US BIOTECH Earnings Per Share (EPS)
[BOM: 541304|NSE : INDOUS]
| Y-o-Y | 96.84 % |
| 5 Yr CAGR | -0.87 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹8.11 | 96.84 | |
| Mar2024 | ₹4.12 | -42.94 | |
| Mar2023 | ₹7.22 | 26.44 | |
| Mar2022 | ₹5.71 | -32.02 | |
| Mar2021 | ₹8.40 | - | |
INDO US BIOTECH Return on Capital Employed (ROCE)
[BOM: 541304|NSE : INDOUS]
| Y-o-Y | 46.67 % |
| 5 Yr CAGR | 3.68 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 21.15% | 46.67 | |
| Mar2024 | 14.42% | -1.37 | |
| Mar2023 | 14.62% | -7.82 | |
| Mar2022 | 15.86% | -13.33 | |
| Mar2021 | 18.3% | - | |
INDO US BIOTECH Share Price vs Sensex
| Current Share Price | : | ₹134.1 |
| Current MarketCap | : | ₹ 269.5 Cr |
| Updated EOD on | : | Nov 12,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | 2.6% |
0.8% |
-48.2% |
| SENSEX | 1.2% |
2.8% |
6.3% |
INDO US BIOTECH related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about INDO US BIOTECH Financials
How the annual revenues of INDO US BIOTECH have changed ?
The Revenues of INDO US BIOTECH have increased by 42.56% YoY .
How the Earnings per Share (EPS) of INDO US BIOTECH have changed?
The Earnings Per Share (EPS) of INDO US BIOTECH has increased by 96.84 % YoY .
Check out Intrinsic Value of Peers of INDO US BIOTECH
Compare Stock Analytics of Peers of INDO US BIOTECH
BOMBAY BURMAH TRADING CORPORATION LTD vs KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD
BOMBAY SUPER HYBRID SEEDS LTD vs INDO US BIOTECH LTD vs
BOMBAY BURMAH TRADING CORPORATION LTD vs KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD
BOMBAY SUPER HYBRID SEEDS LTD vs INDO US BIOTECH LTD vs
